These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10531185)

  • 61. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.
    Wax D; Garofano R; Barst RJ
    Chest; 1999 Oct; 116(4):914-20. PubMed ID: 10531153
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.
    Findlay JY; Plevak DJ; Krowka MJ; Sack EM; Porayko MK
    Liver Transpl Surg; 1999 Sep; 5(5):362-5. PubMed ID: 10477835
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term continuous intravenous infusion of prostacyclin for severe primary pulmonary hypertension.
    Okano Y; Senju S; Tsutsui Y; Kyotani S; Ishibashi M; Yoshida M; Kunieda T
    Intern Med; 1997 Nov; 36(11):794-8. PubMed ID: 9392352
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
    Kerr KM; Rubin LJ
    Chest; 2003 Feb; 123(2):319-20. PubMed ID: 12576339
    [No Abstract]   [Full Text] [Related]  

  • 65. [Continuous intravenous prostacyclin therapy].
    Miyaji K; Matsubara H
    Nihon Rinsho; 2008 Nov; 66(11):2139-44. PubMed ID: 19051733
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension.
    Maron BA; Bhatt DL; Nykiel M; Kinlay S; Waxman AB
    Crit Pathw Cardiol; 2012 Mar; 11(1):40-2. PubMed ID: 22337220
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy.
    Schwerzmann M; Zafar M; McLaughlin PR; Chamberlain DW; Webb G; Granton J
    Int J Cardiol; 2006 Jun; 110(1):104-7. PubMed ID: 15992947
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
    Ataya A; Somoracki A; Cope J; Alnuaimat H
    Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term prostacyclin infusion to reduce pulmonary hypertension in a pediatric cardiac transplant candidate prior to transplantation.
    Kao B; Balzer DT; Huddleston CB; Canter CE
    J Heart Lung Transplant; 2001 Jul; 20(7):785-8. PubMed ID: 11448812
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [A case of primary pulmonary hypertension treated by long-term continuous administration of epoprostenol].
    Yano S; Kobayashi K; Kato K; Tatsukawa T; Ikeda T
    Nihon Kokyuki Gakkai Zasshi; 2005 Jun; 43(6):354-9. PubMed ID: 15997785
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative analysis of Micrococcus luteus isolates from blood cultures of patients with pulmonary hypertension receiving epoprostenol continuous infusion.
    Hirata Y; Sata M; Makiuchi Y; Morikane K; Wada A; Okabe N; Tomoike H
    J Infect Chemother; 2009 Dec; 15(6):424-5. PubMed ID: 20012737
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Nebulized prostacyclin treatment for pulmonary hypertension in a 2-year-old girl].
    Puigarnau Vallhonrat R; Pons Odena M; Carballo Ruano E
    An Esp Pediatr; 2000 Oct; 53(4):372-6. PubMed ID: 11083992
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review.
    Park K; Ostrow D; Levy RD; Swiston J
    Can Respir J; 2011; 18(3):157-62. PubMed ID: 21766080
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
    Horn EM; Barst RJ; Poon M
    Chest; 2000 Oct; 118(4):1229-30. PubMed ID: 11035709
    [No Abstract]   [Full Text] [Related]  

  • 79. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 80. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.
    Shirai Y; Yasuoka H; Takeuchi T; Satoh T; Kuwana M
    Mod Rheumatol; 2013 Nov; 23(6):1211-20. PubMed ID: 23359006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.